ORIGINAL RESEARCH

Burosumab treatment in adults with X-linked hypophosphatemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension

Karine Briot 1, Anthony A Portale, Maria Luisa Brandi, Thomas O Carpenter, Haei Cheong, Martine Cohen-Solal, Rachel K Crowley, Richard Eastell, Yasuo Imanishi, Steven Ing, Karl Insogna, Nobuaki Ito, Suzanne Jan de Beur, Muhammad K Javaid, Peter Kamenicky, Richard Keen, Takuo Kubota, Robin H Lachmann, Farzana Perwad, Pisit Pitukcheewanont, Stuart H Ralston, Yasuhiro Takeuchi, Hiroyuki Tanaka, Thomas J Weber, Han-Wook Yoo, Annabel Nixon, Angela Williams, Mark Nixon, Wei Sun, Angela Williams, Erik A Imel

ABSTRACT

Objectives To report the impact of burosumab on patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphatemia (XLH) through 96 weeks.

Methods Adults diagnosed with XLH were randomised 1:1 in a double-blinded trial to receive subcutaneous burosumab 1 mg/kg or placebo every 4 weeks for 24 weeks (NCT02526160). Thereafter, all subjects received burosumab every 4 weeks until week 96. PROs were measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Brief Pain Inventory—Short Form (BPI-SF) and Brief Fatigue Inventory (BFI), and ambulatory function was measured with the 6 min walk test (6MWT).

Results Subjects (N=134) were randomised to burosumab (n=68) or placebo (n=66) for 24 weeks. At baseline, subjects experienced pain, stiffness, and impaired physical and ambulatory function. At week 24, subjects receiving burosumab achieved statistically significant improvement in some BPI-SF scores, BFI worst fatigue (average and greatest) and WOMAC stiffness. At week 48, all WOMAC and BPI-SF scores achieved statistically significant improvement, with some WOMAC and BFI scores achieving meaningful and significant change from baseline. At week 96, all WOMAC, BPI-SF and BFI achieved statistically significant improvement, with selected scores in all measures also achieving meaningful change. Improvement in 6MWT distance and percent predicted were statistically significant at all time points from 24 weeks.

Conclusions Adults with XLH have substantial burden of disease as assessed by PROs and 6MWT. Burosumab treatment improved phosphate homeostasis and was associated with a steady and consistent improvement in PROs and ambulatory function.

Trial registration number NCT02526160.

Key messages

What is already known about this subject?
► In a phase 3 trial, burosumab significantly increased serum phosphate concentrations compared with placebo over 24 weeks, with a sustained effect on phosphate homeostasis over time, and significantly improved patient-reported outcomes (PROs) from baseline to 48 weeks.

What does this study add?
► We further characterise the cumulative symptom burden of X-linked hypophosphatemia (XLH), showing that adults with XLH experience substantial pain, stiffness, fatigue and impairment in physical and ambulatory function.
► Rapid and persistent improvements in phosphate homeostasis with burosumab treatment are associated with a consistent reduction in the burden of disease associated with XLH, with statistically significant improvements from baseline in PROs and ambulatory function seen as early as week 24 and at week 96, achieving meaningful change from baseline in some pain, stiffness and fatigue scores.

How might this impact on clinical practice or further developments?
► The sustained positive outcomes over time indicate that, despite the long-term cumulative complications and physical impairments associated with XLH, burosumab improves symptoms that are clinically meaningful to adults with XLH, suggesting a role for long-term use of burosumab in improving physical function and quality of life.
INTRODUCTION
X-linked hypophosphataemia (XLH) is a rare, genetic, progressive, lifelong phosphate wasting disease caused by loss-of-function mutations in the PHEx gene (phosphate-regulating endopeptidase homologue, X-linked), which results in excess circulating levels of fibroblast growth factor 23 (FGF23).1 2 The resultant chronic hypophosphataemia and osteomalacia in combination with the irreversible skeletal deformities acquired in childhood are associated with morbidities that develop and progress in adulthood, including osteoarthritis, enthesopathies, fractures, pseudoarthroses and spinal stenosis,3-5 causing bone and joint pain, stiffness, impaired mobility and diminished physical function. These morbidities ultimately decrease health-related quality of life, limit activities of daily living and have a negative psychosocial impact.5-10

Until recently, the only treatment for XLH has been conventional therapy with oral phosphate replacement combined with active vitamin D. Relief of bone pain and healing of pseudoarthroses has been described in a small number of cases in a non-interventional study.11 However, due to the lack of robust trial data evaluating the efficacy of treatment with conventional therapy in adults, along with the known risks of treatment, a frequent practice has been to treat all children but only treat symptomatic adults.12 In a multinational, online survey 49% of adults with XLH were being treated with oral phosphate and 64% with active vitamin D metabolites, with 47% receiving both.8

Burosumab is a fully human monoclonal antibody that binds to excess circulating FGF23 and directly inhibits its activity, thereby correcting the aberrant phosphate homeostasis in adults with XLH. The efficacy of burosumab has been demonstrated in a randomised, double-blind, placebo-controlled phase 3 trial with open-label extension in adults with XLH.13 14 The primary endpoint analysis demonstrated a statistically significant effect of burosumab relative to placebo in increasing serum phosphate concentrations from baseline to week 24.14 Results from the treatment continuation period with all subjects receiving burosumab demonstrated that the effect of burosumab to improve phosphate homeostasis was sustained over 48 weeks.13

Reporting of patient-reported outcomes (PROs) and ambulatory function was limited to the three key secondary endpoints (Brief Pain Inventory-Short Form (BPI-SF) worst pain, Western Ontario and the McMaster Universities Osteoarthritis Index (WOMAC) physical function subscale, WOMAC stiffness subscale) and one exploratory endpoint (change from baseline in 6min walk test (6MWT) distance walked) in the week 24 and week 48 analyses.13 14 Burosumab was associated with improvement in the four patient-relevant endpoints when compared with the placebo-treated group at week 24, however, with Hochberg multiplicity adjustment, only the difference in reduction in WOMAC stiffness was significant between treatments (p=0.012).14 Portale et al13 reported that in both groups, burosumab was associated with clinically significant and sustained improvement from baseline to week 48 in scores for the same four patient-relevant endpoints (p<0.001).

To extend the initial report of the impact of burosumab on PROs and ambulatory function in adults with XLH, we report a change from baseline analysis through week 96 on a wider range of PRO endpoints, using WOMAC, BPI-SF, Brief Fatigue Inventory (BFI) and ambulatory function according to 6MWT, and assess if the change reaches XLH-specific meaningful change benchmarks.

METHODS
Design
The design of this international, randomised, double-blind, placebo-controlled phase 3 study (NCT02526160) has been reported elsewhere and is only briefly described here.13 14

Patient and public involvement
Data collected from adults with XLH via an online survey and through interviews provided insights that informed the decision of which PRO measures to include in the clinical trial.3 6 The XLH Network, a patient advocacy group, was consulted in the development of the survey questions. These data indicated that pain, stiffness and impaired physical function and mobility were substantial issues for adults with XLH, and that the BPI-SF and WOMAC were appropriate to measure deficits. As a result, the decision was made for BPI-SF worst pain score, WOMAC stiffness and WOMAC physical function to be key secondary efficacy endpoints.

Focus groups, in collaboration with The XLH Network, were held with adults with XLH to solicit input regarding the proposed duration of the study, number of site visits required, travel requirements and perceived burden of the assessments to be performed. The XLH Network also distributed recruitment materials to their members to increase awareness of the study. The results of the study were presented by physician speakers to the patient community at The XLH Network events.

Participants
Full inclusion and exclusion criteria are available in Insogna et al.14 Major inclusion criteria were adults (18–65 years old) with a confirmed diagnosis of XLH, biochemical findings consistent with XLH, and the presence of skeletal pain attributed to XLH or osteomalacia. Major exclusion criteria included recent history of traumatic fracture or orthopaedic surgery. For adults receiving therapies affecting phosphate metabolism, these therapies must have been stopped prior to enrolment. Subjects were characterised according to enthesopathies, osteoarthritis, pseudoarthroses and use of opioids or pain medication at baseline.14
Treatment groups

Eligible subjects were randomised 1:1 to receive burosumab (1.0 mg/kg) or placebo administered subcutaneously every 4 weeks for 24 weeks in a double-blinded trial. Thereafter, all subjects entered an open-label treatment continuation period for a further 24 weeks and received burosumab (1.0 mg/kg every 4 weeks). Subjects continued to receive burosumab for an additional 48 weeks during the open-label treatment extension period until week 96.

Subjects randomised to burosumab are referred to as the burosumab–burosumab group, and those randomised to placebo as the placebo–burosumab group. Subjects remained blinded to their original treatment assignment throughout the first 48 weeks of the study.

PROs and ambulatory function endpoints

The objective of the present analysis was to evaluate the effect of burosumab on physical function, stiffness, pain and fatigue (at week 24, 48 and 96; secondary endpoints), and ambulatory function (at week 24, 48 and 72; exploratory endpoint) compared with baseline.

The WOMAC index, BPI-SF and BFI were used for PRO assessments. The WOMAC index, completed at on-site study visits, is a self-reported questionnaire designed to assess pain, stiffness and physical function in subjects with osteoarthritis of the knee or hip, and has been validated in XLH.15 16 The BPI-SF is a self-reported, pain-specific questionnaire measuring pain severity and interference that has been validated in XLH.17 18 Subjects completed all BPI-SF items at the study visit on the day of treatment administration; additionally, subjects also completed the four BPI-SF pain severity items daily in a written diary to more fully characterise pain variability. The BFI is a self-reported, fatigue-specific questionnaire measuring fatigue severity and interference that has been validated in XLH.19 20 Subjects completed the three BFI fatigue severity items in a daily diary and completed the full instrument at the study visit. WOMAC, BPI-SF and BFI endpoints were prespecified, with the exceptions of WOMAC total score, BPI worst pain (greatest), BFI worst fatigue (greatest) and BFI fatigue interference, all of which were post hoc. Table 1 summarises how the score for each PRO instrument was determined in this analysis, including how to interpret XLH-specific meaningful change.21

The 6MWT, used to assess ambulatory function, was administered by a trained clinician in accordance with principles set out in the American Thoracic Society guidelines.22 Subjects were instructed to walk the length of a premeasured course for six consecutive minutes. The total distance walked was recorded in metres; the percent predicted value for the 6MWT was calculated using published normative data based on age, sex and height.23 Here, we report the prespecified endpoints of 6MWT distance walked and 6MWT percent predicted for age and gender.

Statistical analysis

Analyses were conducted for all randomised subjects who received at least one dose of either placebo or burosumab. Continuous variables are summarised using the mean (SD) and categorical variables using number and percentage of subjects. Baseline impairment is described at the item level for all PRO instruments, and the use and type of pain medication being taken at baseline was recorded in subjects’ pain medication diaries.

For the change from baseline analysis, secondary and exploratory endpoints were analysed at a significance level of 5% using a generalised estimating equations model.
(GEE) repeated-measures analysis. Treatment visit and treatment-by-visit interaction were included as categorical variables. Baseline stratification was performed for BPI average pain (>6.0, ≤6.0). The GEE model was applied through week 96 for PRO endpoints and week 72 for 6MWT; the model included p value assessment for within-group change from baseline. Data are presented as least squares mean (SE) change from baseline. Missing data were handled according to the guidelines for each of the three questionnaires and the 6MWT. SAS V.9.4 or higher (SAS Institute) was used for statistical analyses.

RESULTS
In total, 163 subjects were screened, and 134 were enrolled and randomised to burosumab (n=68) or placebo (n=66), with 133 subjects completing the placebo-controlled period; 126 subjects (94.0%) completed week 48 of the treatment continuation period and entered the open-label treatment extension period; and 119 subjects (88.8%) completed the treatment extension period (48–96 weeks). All 134 subjects were included in the present analysis of PROs and ambulatory function.

Mean (SE) exposure to burosumab was 771 (22) days (range 167–957) for the burosumab–burosumab group and 626 (19) days (range 165–844) in the placebo–burosumab group.

Overall, the demographics were similar between treatment groups, as well as between subjects who completed the treatment extension period (n=119) and the total cohort enrolled (N=134) (table 2).

Baseline impairment
At baseline, subjects reported impairment in WOMAC total, physical function, stiffness and pain scores (table 2). Subjects reported notable difficulty going down stairs (50.4% had severe/extreme impairment) and doing heavy household chores (56.0% (severe/extreme)) with stiffness after waking (59% (severe/extreme)) and pain when going up or down stairs (55.6% (severe/extreme)) (figure 1A).

Subjects reported pain and pain interference at baseline, with most subjects (71.6%) having a baseline BPI-SF worst pain (average) score >6.0 (severe) (table 2). The BPI-SF pain interference score showed moderate disruption in activities of daily living due to pain; severe pain when walking, during general activity and during normal work completely interfered with daily life for 11.2%, 8.2% and 9.7% of subjects, respectively (figure 1B).

Subjects reported mean worst fatigue (average) score >6.0 at baseline (table 2). The greatest overall impact was reported for the BFI interference items of walking ability, normal work and enjoyment of life, with the highest fatigue interference scores observed in walking ability (8.3% reported complete interference with daily living) (figure 1C).

Mean 6MWT distance walked was approximately half of the predicted distance based on age and sex, indicating impaired ambulation at baseline (table 2).

Change from baseline
Subjects randomised to receive burosumab in the double-blind period had statistically significant improvements from baseline WOMAC stiffness scores at week 24 (p=0.007; figure 2C). At week 48, after the placebo group had been crossed over to receive burosumab for 24 weeks, the burosumab–burosumab and placebo–burosumab groups had significant improvements from baseline for all WOMAC scores (total score, figure 2A; physical function, figure 2B; stiffness, figure 2C and pain, figure 2D; all p<0.05); similarly at week 96, significant improvements from baseline were evident for all WOMAC scores (all p<0.05). Meaningful change was achieved for WOMAC stiffness in both treatment groups at weeks 48 and 96. For WOMAC physical function, meaningful change was achieved in the burosumab–burosumab group at week 48 and in both treatment arms at week 96. Meaningful change (see table 1 for definition) was also achieved at week 96 in the burosumab–burosumab group for WOMAC total score and WOMAC pain.

Subjects randomised to burosumab had significant improvements from baseline at week 24 in BPI-SF worst pain (average) (p<0.001; figure 3A), BPI-SF worst pain (greatest) (p<0.001; figure 3B) and BPI-SF pain interference (p=0.05; figure 3C). At weeks 48 and 96, improvements from baseline were significant for the burosumab–burosumab and placebo–burosumab groups for all BPI-SF scores (figure 3A–C; all p<0.001). Meaningful change was achieved for worst pain (greatest) in the placebo–burosumab group at week 48 and in both groups at week 96 (figure 3B). For pain interference, meaningful change was achieved in both treatment groups at weeks 48 and 96 (figure 3C).

Subjects randomised to burosumab had significant improvements from baseline at week 24 in BFI worst fatigue (average) (p=0.020; figure 4A) and BFI worst fatigue (greatest) (p=0.004; figure 4B). At week 48, improvements from baseline in worst fatigue (average and greatest) were significant for the burosumab–burosumab and placebo–burosumab groups (both p<0.001; figure 4A and B); for fatigue interference and global fatigue, significant improvements were observed in the placebo–burosumab group at week 48 (all p<0.05; figure 4C and D). At week 96, significant improvement was observed for all fatigue parameters in both groups (all p<0.05). Meaningful change from baseline was achieved for BFI worst fatigue (greatest) at week 48 in the placebo–burosumab group and at week 96 in both groups.

Subjects randomised to burosumab had significant improvements from baseline in 6MWT distance walked (p=0.018; figure 5A) and percent predicted (p=0.021; figure 5B) at week 24. Once all subjects were receiving burosumab at week 48, improvements from baseline in
both 6MWT distance walked and percent predicted were observed in the burosumab–burosumab and placebo–burosumab groups (both p<0.05); statistical significance was also observed at week 72 for both treatment groups (both p<0.05).

**Discussion**

In adults with XLH, further morbidities develop in addition to those that manifest in childhood, including osteoarthritis, enthesopathies, fractures, pseudofractures and spinal stenosis, which can diminish mobility, physical function and quality of life. In this extended analysis of a previously reported phase 3 trial of burosumab in adults with XLH, we describe the high level of impairment at baseline and determine the impact of burosumab treatment on a wide range of PRO and ambulatory function endpoints through week 96 and assess clinical meaningfulness to provide a more complete account of the benefits of burosumab treatment for adults with XLH.
Figure 1  Proportion of adults reporting (A) WOMAC, (B) BPI-SF and (C) BFI item level scores at baseline (N=134). Interference of pain on walking ability and normal work were not recorded at baseline for one participant in each group. BFI, Brief Fatigue Inventory; BPI-SF, Brief Pain Inventory-Short Form; WOMAC, Western Ontario and the McMaster Universities Osteoarthritis.
evaluation of the benefit of burosumab for adults with XLH. Due to the inclusion criteria requiring a BPI-SF worst pain score ≥4, the baseline pain observed in the current study is consistent with or higher than that reported in populations of adults with XLH. In an online survey of 232 adults with XLH, the mean BPI-SF worst pain score was 5.1, indicating pain of moderate severity, with a higher worse pain score of 5.6 for adults who reported a history of fracture. Furthermore, 67% of adults reported using pain medication at least once a week and 21% reported prescription pain medication use. The mean WOMAC pain score at baseline in the present study was greater than that reported in people with rheumatoid arthritis in a population-based survey (49.3 vs 14.9). These data collectively demonstrate that, with current
treatment options, pain is a major issue in adults with XLH.

With burosumab treatment, significant improvement from baseline was seen in pain scores as early as week 24; meaningful change was observed at week 48 for pain interference and at week 96 for worst pain (greatest) and pain interference. The mean age of subjects in this study was 40 years and most had XLH-related musculoskeletal morbidities causing chronic pain, including osteomalacia, osteoarthritis, pseudofractures, fractures and enthesopathies. While pain may be expected to improve with burosumab treatment with the healing of osteomalacia and fractures, some causes of pain may not be amenable to therapies that target FGF23 and thus may not correct the aberrant phosphate homoeostasis in adults with XLH. Osteophytes, osteoarthritis and enthesopathy are structural changes that are unlikely to be affected by treatment with burosumab, thus resulting in residual pain. However, these data indicate that adults with pain due to XLH benefit from burosumab treatment, irrespective of their symptoms and baseline radiographic damage, although within the confines of the study inclusion/exclusion criteria requiring the presence of pain and in a population with a mean age of 40 years.

Pain and stiffness associated with XLH can cause significant disability in adults with XLH. The baseline mean WOMAC stiffness score indicates that adults in this trial experience substantial stiffness compared with the general population. With burosumab, WOMAC stiffness

Figure 4 Change from baseline in BFI (A) worst fatigue (average), (B) worst fatigue (greatest), (C) global fatigue and (D) fatigue interference scores (N=134). Data show LS mean (±SE); lower scores indicate lower fatigue severity and less fatigue interference. *p<0.05 for LS mean change from baseline. †Indicates the minimal clinically important difference from baseline (≥−1.5 worst fatigue (average, greatest), ≥−1.2 global fatigue, ≥−1.2 fatigue interference, shown by the pale grey horizontal line). BFI, Brief Fatigue Inventory; LS, least squares.

Figure 5 Change from baseline in 6MWT (A) distance walked (metres) and (B) percentage predicted (%) (n=132). Data show LS mean (±SE); higher scores indicate better ambulatory function. *p<0.05 for LS mean change from baseline. 6MWT, 6min walk test; LS, least squares.
showed significant improvement from baseline as early as week 24. Importantly, meaningful improvement was observed with burosumab at week 48 and at week 96.

The improvements in PROs observed through to 96 weeks highlight the potential benefits of continued burosumab treatment over time. Despite the long-term cumulative complications and physical impairments, maintenance of treatment with burosumab improves symptoms that are clinically meaningful to adults with XLH. This is the first randomised placebo-controlled trial to show therapeutic improvement of patient-relevant musculoskeletal symptoms in adults with XLH over 96 weeks using PRO endpoints that have not been previously reported and with an evaluation of whether observed change from baseline achieved XLH-specific minimal clinically important differences (MCIDs).

This present analysis has several limitations. The subjects of the trial were adults with XLH who were symptomatic despite prior exposure to conventional therapy. After 24 weeks, burosumab treatment was given open label to all subjects; however, subjects and investigators remained blinded to the original treatment assignments until the week 48 analysis was completed to minimise bias. Furthermore, the trial was designed vs placebo to week 24; therefore, analysis of this trial is unable to provide data on the efficacy of conventional therapy on patient-relevant outcomes.

In the trial, there was no radiographical follow-up for the subjects, and as such it is not possible to correlate the PRO changes with some of the potential structural changes.

Subjects were required to maintain a stable dose and schedule of pain medication up to week 24, after which time pain medication could be adjusted as necessary. Although data were collected on change in pain medication use at 24–48 weeks, the analysis and interpretation of the use of pain medication in a clinical trial and over a short time frame is challenging and contrived. The utilisation of pain medication with burosumab treatment should be investigated in the future using real-world evidence from observational studies.26

Finally, although XLH-specific MCIDs have been calculated and published,16,17,20 these are preliminary, and additional work is required to derive MCIDs in larger samples of subjects with XLH and XLH-specific MCIDs for 6MWT distance.

In conclusion, adults with XLH experience substantial burden of disease as a result of musculoskeletal morbidities that have developed despite current treatment options, causing symptoms of pain, stiffness and fatigue, as well as impairment in physical and ambulatory function. Statistically significant improvements from baseline in PROs and ambulatory function were observed early and persisted up to week 96 with burosumab treatment, with predefined meaningful changes observed in pain, stiffness and fatigue. Together, these findings demonstrate that the rapid and sustained improvement in phosphate homoeostasis induced by burosumab treatment is associated with sustained reduction in the substantial burden of disease that has accumulated over the lifetime in adults with musculoskeletal pain related to XLH and suggest that long-term use of burosumab has a role in improving these outcomes in adults with XLH.

Author affiliations
1Department of Rheumatology, Hôpital Cochin, Paris, France
2Department of Pediatrics, Division of Nephrology, University of California, San Francisco, California, USA
3FIRM Foundation, Florence, Italy
4Department of Pediatrics and Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, Connecticut, USA
5Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Republic of Korea
6Department of Rheumatology, Hôpital Lariboisière, Paris, France
7INSERM U1132 BIOSCAR, University of Paris, Paris, France
8Department of Endocrinology, St Vincent’s University Hospital, Dublin, Ireland
9University College Dublin School of Medicine, Dublin, Ireland
10Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK
11Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
12Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
13Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA
14Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan
15Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
16Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
17Endocrine Physiology and Pathophysiology, INSERM, Paris-Saclay University, Paris, France
18Hospital Bicêtre, Paris, France
19Metabolic Bone Disease Unit, Royal National Orthopaedic Hospital NHS Trust, London, UK
20Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
21Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK
22Department of Pediatric Endocrinology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA
23Rheumatology and Bone Diseases Unit, Medical Research Council Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK
24Endocrine Center, Toranomon Hospital, Tokyo, Japan
25Department of Pediatrics, Okayama Saiseikai General Hospital, Okayama, Japan
26Division of Endocrinology, Metabolism and Nutrition, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
27Department of Pediatrics, Asan Medical Center Children’s Hospital, Seoul, Republic of Korea
28Chilli Consultancy, Salisbury, UK
29Biostatistics Department, Kyowa Kirin Pharmaceutical Development, Inc, Princeton, New Jersey, USA
30Health Economics and Outcomes Research Department, Kyowa Kirin International PLC, Marlow, UK
31Department of Medicine and Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA

Acknowledgements The authors thank the participants, caregivers and healthcare professionals who participated in this study. Medical writing and editorial support were provided by OPEH Health Media Communications, with funding provided by Kyowa Kirin International; the authors retain full editorial control over the content and the decision to publish.

Contributors KB, AAP, MLB, TOC, HIC, MC-S, RKC, RE, YI, SI, KL, NI, SDJR, MKJ, PK, RK, TK, RHL, FP, PP, SHR, YT, HT, TJW, H-WY and EAI were investigators on the
evaluate the suitability of the BPI-SF and WOMAC® as clinical trial end points. *Value Health* 2018;21:973–83.


